ALDX Stock Summary and Trading Ideas (Aldeyra Therapeutics | NASDAQ:ALDX)

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics trades on the NASDAQ stock market under the symbol ALDX.

As of January 13, 2025, ALDX stock price declined to $4.84 with 62,712 million shares trading.

ALDX has a beta of 1.06, meaning it tends to be more sensitive to market movements. ALDX has a correlation of 0.02 to the broad based SPY ETF.

ALDX has a market cap of $288.22 million. This is considered a Small Cap stock.

In the last 3 years, ALDX traded as high as $11.97 and as low as $1.42.

The top ETF exchange traded funds that ALDX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

ALDX has outperformed the market in the last year with a price return of +44.9% while the SPY ETF gained +22.7%. However, in the short term, ALDX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -9.0% vs +0.6% return in SPY. But in the last 2 weeks, ALDX shares have fared better than the market returning -2.0% compared to SPY -2.9%.

ALDX support price is $4.73 and resistance is $5.15 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALDX shares will trade within this expected range on the day.